
Cue Biopharma, a clinical-stage biopharmaceutical company is developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease. Cue Biopharma’s proprietary platform, Immuno-STAT® (Selective Targeting and Alteration of T Cells) and biologics are designed to harness the curative potential of the body’s innate immune system through the selective modulation of disease-relevant T cells without the adverse effects of broad systemic immune activation.
Annual Revenue$10M to $25M
Estimated OwnershipPublicBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.